1. Scrip

Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li

New R&D Head Comes From Discovery And Translation Group

 
• By Mandy Jackson

Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.  

a hand with an antique skeleton key toned with a retro vintage filter instagram app or action effect
Perlmutter will pass the Merck Research Laboratories keys to Li on 1 January • Source: Shutterstock

Merck & Co., Inc. is in better shape now than it was in 2013 when Roger Perlmutter rejoined the big pharma as president of Merck Research Laboratories, largely because of the mega-blockbuster Keytruda. Now, the company announced on 2 October, Perlmutter is retiring and handing over ongoing research and development of the PD-1 inhibitor as well as the R&D group’s efforts to generate novel products to Dean Li, senior vice president of discovery sciences and translational medicines.

Perlmutter will officially hand over the MRL keys to Li on 1 January but will remain as executive director of the organization through 30 June 2021 to facilitate the R&D...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.